EF
MRNA icon

Empowered Funds’s Moderna MRNA Stock Holding History

Empowered Funds’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.42M Buy
63,142
+29,706
+89% +$1.54M 0.02% 764
2026
Q1 		$1.7M Buy
33,436
+19,704
+143% +$919K 0.01% 1192
2025
Q4 		$405K Buy
13,732
+353
+3% +$9.59K 0.01% 789
2025
Q3 		$346K Buy
13,379
+242
+2% +$6.75K ﹤0.01% 1551
2025
Q2 		$362K Buy
+13,137
New +$346K ﹤0.01% 1438
2025
Q1 		– Sell
-5,781
Closed -$240K – 1729
2024
Q4 		$240K Buy
5,781
+582
+11% +$27.8K ﹤0.01% 1451
2024
Q3 		$347K Buy
5,199
+322
+7% +$29.6K 0.01% 1211
2024
Q2 		$579K Buy
4,877
+601
+14% +$76.1K 0.01% 1010
2024
Q1 		$456K Buy
4,276
+904
+27% +$91.1K 0.01% 1101
2023
Q4 		$335K Buy
3,372
+611
+22% +$51.4K 0.01% 1084
2023
Q3 		$285K Buy
2,761
+504
+22% +$56.2K 0.01% 1070
2023
Q2 		$274K Buy
2,257
+822
+57% +$110K 0.01% 991
2023
Q1 		$220K Buy
+1,435
New +$237K 0.01% 491
2022
Q3 		– Sell
-31,902
Closed -$4.56M – 360
2022
Q2 		$4.56M Buy
+31,902
New +$4.56M 0.59% 37
2021
Q4 		– Sell
-4,306
Closed -$1.66M – 276
2021
Q3 		$1.66M Buy
+4,306
New +$1.59M 0.21% 105

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Empowered Funds's MRNA Position: Q2 2026 in Review

Empowered Funds increased its Moderna (MRNA) stake by 89% in Q2 2026, buying an estimated $1.54M and bringing the position to 63,142 shares worth $4.42M. The position accounts for 0.02% of the portfolio, ranked #764.

Empowered Funds first reported a position in MRNA in Q3 2021 and has held it in 15 quarters since. The position peaked at $4.56M in Q2 2022. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Empowered Funds held 63,142 shares of Moderna worth $4.42M as of Q2 2026.
  • Empowered Funds bought 29,706 Moderna shares in Q2 2026, an estimated $1.54M.
  • Moderna made up 0.02% of Empowered Funds's portfolio in Q2 2026, its #764 holding.
  • Empowered Funds first reported a position in Moderna in Q3 2021 and has held it in 15 quarters since.
  • Empowered Funds's Moderna position peaked at $4.56M in Q2 2022.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.